Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line study of amivantamab + lazertinib versus osimertinib or lazertinib in EGFR-mutant advanced non-small cell lung cancer
CTR20202472Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of amivantamab, lazertinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Apr 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202472.